AI Article Synopsis
- B-Cell Lymphoproliferative Disorders (B-LPDs) are characterized by the accumulation of B-cells in various parts of the body and present diagnostic challenges due to their similar features and varied outcomes.
- Accurate diagnosis through immunophenotyping by flow cytometry is crucial, and the recent discovery of CD200's differential expression aids in distinguishing between similar disorders like chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL).
- A study analyzing 100 samples revealed that while all CLL cases expressed CD200, 6 MCL cases showed no expression, highlighting CD200’s potential role in improving clinical diagnosis and treatment strategies.
Article Abstract
B-Cell Lymphoproliferative Disorders (B-LPDs) are a group of heterogenous disorders characterised by the accumulation of B-cells in peripheral blood, bone marrow, lymph nodes and spleen. They have a variable disease course and outcome and many share similar features making differential diagnosis challenging. Therefore, accurate diagnosis is fundamental in particular for determining treatment options. Immunophenotyping by flow cytometry plays a crucial role in the diagnosis of B-LPDs. However, overlapping immunophenotyping patterns exist and the use of novel monoclonal antibodies has become increasingly important in immunophenotyping analysis. More recently differential expression of CD200 has been reported in various B-LPDs and that CD200 may improve the differentiation between chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). In this study CD200 expression is evaluated in different B-LPDs. A total of 100 samples were collected and analysed by immunophenotyping flow cytometry over a period of 1 year (2017-2018), by a panel of monoclonal antibodies including CD200. The percentage of CD200 and its expression intensity was evaluated and compared between different groups of B-LPDs. All of the 50 cases of CLL expressed CD200 with moderate to bright intensity, 6 MCL cases lacked the expression of CD200. Furthermore, all 5 cases of hairy cell leukaemia (HCL) expressed CD200. Out of all B-LPDs evaluated, CD200 expression in HCL cases was noted to be the brightest. The other 39 cases were not found to be B-LPDs. CD200 has an important role in differentiating CLL from MCL, HCL has a consistent bright expression of CD200. By adding CD200 to the combinations of markers in routine testing panel, Immunophenotyping by flow cytometry can be an effective tool in the diagnosis of B-LPDs especially in cases with atypical immunophenotyping pattern. Our result support that CD200 can be added to routine testing panel as it is useful in differentiating them.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563807 | PMC |
| http://dx.doi.org/10.3389/bjbs.2023.11573 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bone marrow niches orchestrate stem-cell hierarchy and immune tolerance.
Nature
January 2025
Columbia Center for Translational Immunology, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Stem cells reside in specialized microenvironments, termed niches, at several different locations in tissues. The differential functions of heterogeneous stem cells and niches are important given the increasing clinical applications of stem-cell transplantation and immunotherapy. Whether hierarchical structures among stem cells at distinct niches exist and further control aspects of immune tolerance is unknown.
View Article and Find Full Text PDFCorrelation between conventional karyotype, interphase FISH and immunophenotype in risk stratification of newly diagnosed plasma cell myeloma: An observational study.
Med J Armed Forces India
December 2024
Professor (Lab Sciences & Molecular Medicine), Army Hospital (R&R), Delhi Cantt, India.
Background: Plasma cell myeloma (PCM) is a common adult hematological neoplasm of terminally differentiated B-cells resulting in accumulation of monoclonal plasma cells. PCM is heterogeneous disease with survival time varies from months to years, determined by age, stage, cytogenetics abnormalities, and treatment response. There is conflicting evidence in role of immunophenotype as a prognostic indicator.
View Article and Find Full Text PDFGum Arabic Enhances Hair Follicle-Targeting Drug Delivery of Minoxidil Nanocrystal Dispersions.
Biol Pharm Bull
December 2024
Faculty of Pharmacy, Kindai University.
In this study, we attempted to enhance the delivery of minoxidil (MXD) nanocrystals into hair follicles for efficacious hair growth treatment. We applied a bead milling method and designed an MXD nanocrystal dispersion containing methylcellulose (MC) and gum arabic (GA), termed MG-MXD@NP, with a particle size of 110 nm. In vivo studies in C57BL/6 mice showed that MG-MXD@NP improved MXD delivery to the skin tissue, hair bulges, and hair bulbs, resulting in earlier and superior hair growth compared with a commercially available MXD lotion (Riup 5%, CA-MXD).
View Article and Find Full Text PDFCoagulation factor II thrombin receptor as a promising biomarker in breast cancer management.
Open Life Sci
December 2024
Department of General Surgery, The Second Affiliated Hospital of Air Force Medical University, No. 356 of Xinsi Road, Baqiao District, Xi'an, 710038, China.
This study aims to comprehensively investigate the role of coagulation factor II thrombin receptor (F2R) in breast cancer (BC) and to evaluate its potential as a biomarker in this context. Data on female BC were retrieved from the TCGA database. Comparative analyses were performed, including enrichment analysis, tumor immune microenvironment analysis, drug sensitivity testing, molecular docking, and cell-based experiments, to assess the expression and function of F2R in BC.
View Article and Find Full Text PDFFirst-in-human study of 23ME-00610, an antagonistic antibody for genetically validated CD200R1 immune checkpoint, in participants with advanced solid malignancies.
Cancer Res Commun
December 2024
South Texas Accelerated Research Therapeutics, San Antonio, TX, United States.
Purpose: In this Phase 1 portion of a first-in-human Phase 1/2a study (NCT05199272), 23ME-00610 was evaluated in participants with advanced solid malignancies to determine its safety, tolerability, pharmacokinetics, and pharmacodynamics. Exploratory biomarkers were evaluated to examine potential correlates of efficacy and safety.
Patients And Methods: Eligible participants (≥18 years) were administered 23ME-00610 intravenously every 3 weeks using an accelerated titration design followed by a traditional 3+3 design, with an initial dose level of 2 mg.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!